Castle Biosciences SEC Filings

Castle Biosciences (CSTL) Form 4: Chief Financial Officer Frank Stokes reported an open-market sale of 5,388 shares of common stock on 11/11/2025 at a weighted-average price of $35.08. The filing notes multiple trades executed between $34.44 and $35.37. Following the transaction, Stokes beneficially owns 43,328 shares, held directly. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on 08/12/2025.

Castle Biosciences (CSTL) reported an insider transaction by its Chief Commercial Officer on Form 4. The officer sold 500 shares of common stock on 11/11/2025 at a weighted-average price of $35.39 pursuant to a Rule 10b5-1 plan adopted on September 11, 2024. A separate sale of 200 shares occurred on 11/12/2025 at $35.40.

Following these transactions, the officer reported 84,027 shares held directly. In addition, 2,230 shares are held indirectly by the Tobin W and Susan M Juvenal Family Revocable Trust, of which the officer and spouse are trustees and beneficiaries include the officer, spouse, and their children.

Castle Biosciences (CSTL) reported an insider transaction by its Chief Operating Officer. On November 11, 2025, the COO sold 18,932 shares of common stock (code S) under a Rule 10b5-1 plan adopted on March 6, 2025 at a $35.10 weighted-average price, with trade prices ranging from $35.00 to $35.37.

Following the transactions, the reporting person beneficially owns 12,323 shares directly and 97,251 shares indirectly via The Fritz Shorter Trust. The filing also notes a transfer of 3,686 shares from the trust to direct holdings on November 11, 2025.

Castle Biosciences (CSTL) reported insider transactions by President & CEO and Director Derek Maetzold. Under a Rule 10b5-1 plan adopted on May 8, 2025, he sold 6,458 shares on 11/04/2025 at a weighted-average price of $30.413, 237 shares on 11/04/2025 at $31.117, and 2,678 shares on 11/05/2025 at $31.851.

Following these sales, he held 53,615 shares directly. He also reports indirect holdings through family trusts, including 85,959 shares in DJM Grantor Retained Annuity Trust No. 5.

Castle Biosciences (CSTL) disclosed that its Chief Operating Officer reported an open-market sale of 12,678 shares of common stock on 10/31/2025 at a weighted-average price of $25.04, executed in multiple trades within a $25.00–$25.12 range. The sale was made pursuant to a Rule 10b5-1 plan adopted on March 6, 2025.

Following the transaction, the reporting person beneficially owns 27,569 shares directly and 100,937 shares indirectly through The Fritz Shorter Trust.

Castle Biosciences (CSTL): Form 4/A amendment reports that the Chief Operating Officer sold 18,007 shares of common stock on 08/27/2025 at a weighted-average price of $21.69, with trades executed between $21.24 and $21.94. The amendment clarifies the sale was made by the Fritz Shorter Trust, not directly by the executive.

Following the sale, holdings were 52,924 shares held directly and 100,937 shares held indirectly through the Trust. The filing also notes prior transfers to the Trust of 96,322 shares on March 19, 2025 and 22,622 shares on August 22, 2025.

Castle Biosciences, Inc. (CSTL) filed a Form S-8 to register 700,000 additional shares of common stock under its Castle Biosciences, Inc. 2022 Inducement Plan. The filing uses General Instruction E to register additional securities of the same class and incorporates prior S-8 filings by reference.

The company references its 2024 Form 10-K and 2025 quarterly and current reports for incorporation by reference, and lists standard exhibits including a legal opinion and auditor consent. Castle Biosciences identifies itself as an accelerated filer, and the registration statement is signed by President and CEO Derek J. Maetzold.

Castle Biosciences (CSTL) reported Q3 2025 results. Net revenues were $83.0 million versus $85.8 million a year ago, and the quarter showed a net loss of $0.5 million compared with net income of $2.3 million. For the nine months, net revenues reached $257.2 million, up from $245.8 million, while the company posted a net loss of $21.8 million versus income of $8.7 million last year.

Operating expenses rose on higher cost of sales and SG&A, and year‑to‑date amortization increased after the discontinuation of IDgenetix, which accelerated $20.1 million of expense. The balance sheet remained strong with cash and cash equivalents of $85.6 million and marketable investment securities of $202.0 million as of September 30, 2025. Year‑to‑date cash provided by operating activities was $37.4 million.

Dermatologic testing contributed $48.5 million and non‑dermatologic $34.5 million in Q3. The company closed an asset acquisition of Capsulomics (developed technology valued at $28.2 million) and entered a collaboration with SciBase. Long‑term debt stood at $10.0 million; the interest‑only period on the term loan was extended to December 1, 2026.

Castle Biosciences (CSTL) furnished an update on its business by announcing financial results for the third quarter ended September 30, 2025, via a press release attached as Exhibit 99.1. The company also made available an investor slide presentation as Exhibit 99.2.

The materials were furnished under Items 2.02 and 7.01 and are not deemed “filed” for purposes of Section 18 of the Exchange Act, nor incorporated into other filings except by specific reference.